Cheryl Ann Stouch - Jul 31, 2025 Form 4 Insider Report for Mallinckrodt plc

Role: EVP & Chief Info Officer
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Transactions as of: Jul 31, 2025
Transactions value $: $0
Form type: 4
Date filed: 8/4/2025, 08:50 PM
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Stouch Cheryl Ann	EVP & Chief Info Officer	675 MCDONNELL BLVD., HAZELWOOD	/s/ Mark Tyndall, Attorney-in-Fact	2025-08-04	0002077699

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction		Ordinary Shares	Award		+631			631	Jul 31, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction		Restricted Stock Units	Award	$0	+8.51K		$0.00	8.51K	Jul 31, 2025	Ordinary Shares	8.51K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. At the Merger Effective Time (as defined in the Transaction Agreement), each share of Endo common stock held by the reporting person immediately prior to the Merger Effective Time automatically converted into the right to receive approximately $1.31 in cash and 0.2575 ordinary shares of the Issuer without interest and subject to applicable withholding.
F2	Effective at the Merger Effective Time, (i) each restricted stock unit in respect of Endo common stock ("Endo RSU") held by the reporting person immediately prior to the Merger Effective Time automatically converted into a restricted unit in respect of a number of ordinary shares of the Issuer ("Issuer RSU") determined in accordance with the formula set forth in the Transaction Agreement and (ii) each performance-based restricted stock unit in respect of Endo common stock ("Endo PSU") held by the reporting person immediately prior to the Merger Effective Time automatically converted into an Issuer RSU in respect of the number of ordinary shares of the Issuer determined in accordance with the formula set forth in the Transaction Agreement assuming the performance goals were achieved based on target performance.
F3	The Issuer RSUs will vest ratably on April 23, 2026 and April 23, 2027. Upon vesting, each Issuer RSU will be settled in ordinary shares of the Issuer at one share per Issuer RSU.

Remarks:

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.